Novo CSO on newly purchased drug: "It could become the first and best of its kind"
Through the purchase of Corvidia Therapeutics, Novo Nordisk has secured an innovative treatment for cardiovascular disease, which expands the company's cardiovascular portfolio beyond diabetes, says research director Mads Krogsgaard Thomsen.
BY KEVIN GRØNNEMANN, TRANSLATED BY CATHERINE BRETT
When Novo Nordisk paid up to DKK 14 billion (USD 2.1 billion) to purchase US biotech company Corvidia Therapeutics, the company also threw itself into a new effort within cardiovascular disease.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
